Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bolten, C. W
Right arrow Articles by Colca, J. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolten, C. W
Right arrow Articles by Colca, J. R
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat

Charles W Bolten

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Maria A Payne

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

William G McDonald

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Patrick M Blanner

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Robert C Chott

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Sarbani Ghosh

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Graciela B Arhancet

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Nicholas R Staten

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Eric A Gulve

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Patrick M Sullivan

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Alexander E Hromockyj

Discovery Research, Pfizer Corporation, 700 Chesterfield Parkway West, Chesterfield, MO 63017, US.

Jerry R Colca

Kalamazoo Metabolic Research, 125 S. Kalamazoo Mall #604, Kalamazoo, MI 49007, US.

We evaluated the effects of two thiazolidinediones (TZDs), the potent PPAR{gamma} agonist rosiglitazone currently being used to treat diabetes, and a structurally similar experimental compound that is a poor PPAR{gamma} agonist, in a non-diabetic, established hypertension model with continuous measurement of blood pressure by telemetry. Hypertension was induced in male Dahl salt-sensitive rats by a three-week pre-treatment with 4% salt before initiation of treatment. Fasting blood samples were taken for analysis of a biomarker panel to assess metabolic, anti-inflammatory and antioxidant activity of the treatments. Both TZDs significantly reduced both systolic and diastolic blood pressure. When used at the maximally effective doses established for metabolic improvement, both compounds produced equivalent reduction in lipids and elevation of adiponectin, yet the poorer PPAR{gamma} agonist produced significantly greater reductions in blood pressure. Neither compound had a significant effect on circulating glucose or insulin in this animal model.

The data demonstrate that these TZDs lower blood pressure significantly in Dahl rats and that this cardiovascular pharmacology is not directly correlated with the metabolic actions or with the magnitude of PPAR{gamma} activation. These data suggest that it may be possible to find insulin-sensitising agents that have beneficial cardiovascular pharmacology with broad applications for disease prevention.

Key Words: Dahl rats • insulin resistance • metabolic hypertension • thiazolidinediones

Diabetes and Vascular Disease Research, Vol. 4, No. 2, 117-123 (2007)
DOI: 10.3132/dvdr.2007.029
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Venegas-Pont, J. C. Sartori-Valinotti, C. Maric, L. C. Racusen, P. H. Glover, G. R. McLemore Jr., A. V. Jones, J. F. Reckelhoff, and M. J. Ryan
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1282 - R1289.
[Abstract] [Full Text] [PDF]